Innovations in Antiarrhythmic Drug Therapy: Oxymoron or a Turning Point in the Field

Catheter ablation has become the dominant form of therapeutic intervention for cardiac arrhythmias. However, preclinical development of new antiarrhythmic drugs is very robust. These new molecular entities are not limited to antagonism of membrane active ion channels, but target additional mechanisms of arrhythmogenesis. These drugs, their targets, and their potential ability to improve and disrupt current care paradigms will be reviewed in this session.